| Literature DB >> 26244933 |
Shweta Bhatt1, Manoj K Gupta1, Mogher Khamaisi2, Rachael Martinez3, Marina A Gritsenko4, Bridget K Wagner5, Patrick Guye6, Volker Busskamp7, Jun Shirakawa1, Gongxiong Wu8, Chong Wee Liew1, Therese R Clauss4, Ivan Valdez1, Abdelfattah El Ouaamari1, Ercument Dirice1, Tomozumi Takatani1, Hillary A Keenan2, Richard D Smith4, George Church7, Ron Weiss6, Amy J Wagers9, Wei-Jun Qian4, George L King2, Rohit N Kulkarni10.
Abstract
The mechanisms underlying the development of complications in type 1 diabetes (T1D) are poorly understood. Disease modeling of induced pluripotent stem cells (iPSCs) from patients with longstanding T1D (disease duration ≥ 50 years) with severe (Medalist +C) or absent to mild complications (Medalist -C) revealed impaired growth, reprogramming, and differentiation in Medalist +C. Genomics and proteomics analyses suggested differential regulation of DNA damage checkpoint proteins favoring protection from cellular apoptosis in Medalist -C. In silico analyses showed altered expression patterns of DNA damage checkpoint factors among the Medalist groups to be targets of miR200, whose expression was significantly elevated in Medalist +C serum. Notably, neurons differentiated from Medalist +C iPSCs exhibited enhanced susceptibility to genotoxic stress that worsened upon miR200 overexpression. Furthermore, knockdown of miR200 in Medalist +C fibroblasts and iPSCs rescued checkpoint protein expression and reduced DNA damage. We propose miR200-regulated DNA damage checkpoint pathway as a potential therapeutic target for treating complications of diabetes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26244933 PMCID: PMC4589213 DOI: 10.1016/j.cmet.2015.07.015
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287